



22 May 2013

Company Announcements Office  
Australian Stock Exchange  
Level 6, 20 Bridge Street  
Sydney NSW 2000

### **Anteo Enters Into Sales Partnership Agreement With Genova Scientific**

- **Genova to purchase Mix&Go™ from Anteo for distribution into Europe and Latin America**
- **Target customers are in industrial and academic research**
- **Revenues from sales to be shared between the two companies**
- **Genova is a Spanish company that develops and sells products and advanced technologies into the life sciences and clinical diagnostic healthcare segments**
- **Agreement non-exclusive with a 12 month renewable term**

**22 May 2013: Anteo Diagnostics Limited (ASX: ADO) (“Anteo”)** and Genova Scientific (“Genova”) are pleased to announce that they have entered into a Sales Partnership Agreement. Genova will make Anteo’s Mix&Go™ surface chemistry available to its growing base of researchers in Europe and Latin America.

Genova is a privately held company located in Sevilla, Spain. The company develops and sells a wide range of antibodies and other products for immunochemistry, histology and flow cytometry applications to life science researchers. They also develop and supply clinical diagnostic products to customers in Europe, predominantly Spain and Portugal, and Latin America.

Under this Agreement Anteo will sell Mix&Go™ surface chemistry to Genova and Genova will distribute co-branded product to their customers in industrial and clinical research. The Mix&Go™ sold by Genova can be used by customers to functionalise a wide variety of beads, biosensor surfaces, glass slides and microtitre plates. Additional products may be added based on customer requests. Sales revenues will be shared by the two companies.

The Sales Partnership with Genova will enable Anteo to gain exposure for Mix&Go™ amongst scientists in both Europe and Latin America, two large markets Anteo has so far not systematically addressed. Mix&Go™ takes a novel approach to attaching large fragile biomolecules such as proteins to various surfaces used in R&D and diagnostics. The product, which can be envisaged as a “molecular Velcro”, binds these biomolecules gently yet firmly so they don’t suffer any loss in activity.

Genova’s Chief Executive Officer Ms Carmen Pérez said “The Agreement with Anteo beneficially extends our product range and provides major advantages for our customers.”

***Anteo Diagnostics Limited* ABN 78 090 487 273**  
**Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113**

**Phone 07 3219 0085 Fax 07 3219 0553 Email [contact@anteodx.com](mailto:contact@anteodx.com) Web [www.anteodx.com](http://www.anteodx.com)**

For personal use only

Anteo's Chief Executive Officer Dr Geoff Cumming said: "We are looking forward to working with Genova and, through their distribution networks, establishing an increased awareness of the benefits that Mix&Go™ offers in highly relevant markets."

In addition to this Agreement the two companies are investigating a number of products in development that may be improved through the inclusion of Mix&Go™.

ENDS

**For More Information Contact:**

**Dr Geoff Cumming, CEO**  
**Anteo Diagnostics Limited**  
**Tel: +61 2 8823 3110**

**Sam Sloane**  
**Six Degrees Investor Relations**  
**Tel: +61 2 9230 0661**

***Anteo Diagnostics Limited*** ABN 78 090 487 273  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)

For personal use only